Author: 5hspx

LONDON — European stocks opened higher on Wednesday, rebounding as investors await comment from the U.S. Federal Reserve on its inflation and interest rate outlook. The region's Stoxx 600 index closed lower on Tuesday, halting a strong rally that had been underway since the global selling pressure of Aug. 1-5. France's CAC 40 was last up seven points to 7,490, Britain's FTSE 100 was up four points and Germany's DAX was up 10 points, according to IG Data. It's been a quiet week on the European data front, apart from the release of flash euro zone purchasing managers' index figures…

LONDON — European stocks opened modestly higher on Wednesday, cautiously rebounding after a long winning streak was snapped on Tuesday.The pan-European Stoxx 600 index was up 0.1% as of 8:33 a.m. London time, with sectors mixed: mining stocks rose 1.26% and communications stocks were down 0.2%.Regional stock indexes closed lower on Tuesday, halting a strong run that had continued since the global selling pressure from August 1-5.Stock Chart IconStock Chart IconStoxx 600 Index.The Office for National Statistics said on Wednesday that net borrowing by the U.K. public sector rose to 3.1 billion pounds ($4.037 billion) in July, up 1.8 billion…

GRANTS AWARDED — Encino Energy Vice President of External Relations Jackie Stewart, center, presented the Jefferson County Board of Health with a check for $3,790 on Tuesday, a gift from Encino’s Community Partnership Program. From left, board members Suzanne Brown, Mary Mihalio, Dr. Mark Kissinger, Stewart, board member Terry Bell, Health Director Andrew Henry and board member Anthony Mugianis. — Christopher Dacanai SENSORY-FRIENDLY — Jefferson County Integrated Health District Health Director Andrew Henry demonstrated the health department’s new portable sensory tower, acquired from the nonprofit Culture City through an Encino Energy Community Partnership Program grant. — Christopher Dacanai EQUIPMENT —…

Amazon Web Services CEO Matt Gurman has reportedly suggested that artificial intelligence could take over much of the coding work. What happened: Gurman's comments during the June fireside chat weren't intended as a doomsday prediction, but rather as a kind message to software engineers, Business Insider reported, citing an audio recording of the meeting obtained by Business Insider. “If we look 24 months from now, or even further out — I can't predict exactly when that will be — it's possible that most developers won't be coding,” Gurman said. The AWS CEO, who took over in June, has envisioned a…

Noteya Innovations, an international business acceleration and project management consulting firm, today announced that Chan Phanmok has been selected as the firm's new partner and promoted to Director of Corporate Accounts. As a Partner at Noteya, Chan will play a key role in the firm's corporate leadership and strategic direction. In his new role as Corporate Account Director, he will manage the firm's key international client and partner accounts, and be responsible for client services and project operations. Noteya manages a global network of sales channels and business partners, including prominent System Integrators, Value Added Resellers (VARs) and Managed Service…

Santa Fe TradFest asks a simple question: Do you love acoustic instruments?If you count the old Santa Fe Banjo & Fiddle Contest, which was the prototype for the ongoing Santa Fe TradFest, the annual three-day traditional music festival will celebrate its 50th anniversary in 2024. For five decades, it's been home to folk, Americana, bluegrass, regional tunes and more acoustic guitars, banjos, upright basses and fiddles than you could ever imagine.”Thanks to support from the state, city and community, we've been in the black for eight years, which is great for a nonprofit,” organizer Dave Dillman said.Dillman serves on the…

<\/div><\/div>”),”filter”:{“nextExceptions”:”img, blockquote, div”,”nextContainsExceptions”:”img, blockquote, a.btn, a.o-button”},”renderIntial”:true,”wordCount”:350}”> When I had the chance to spend some time in Europe this year, the first thing I wanted to do—well, besides find some really good cheese—was figure out how to visit as many national parks as possible. As the editor in chief of National Park Trips, Outside’s sister brand, I spend a lot of time thinking about national parks. Whether it’s figuring out how to pack as much as possible into a weekend in Yellowstone, thinking about the implications of reservation systems, or dreaming about units to visit, I eat, sleep, and breathe America’s…

AI gone wild: How Grok-2 pushes the boundaries of ethics and innovationAdobe Stock As AI continues to evolve at breakneck speed, Elon Musk's latest creation, Grok-2, is taking the tech world by storm. This powerful new AI model not only pushes the boundaries of what's technically possible, but also challenges notions of AI ethics and responsibility. Let's dive into the fascinating yet controversial world of Grok-2 and explore what it means for the future of AI. The Rise of Grok-2: A New AI Powerhouse The latest product from Musk's xAI company, Grok-2, is designed to be an all-rounder in the…

Allschwil, Switzerland, August 21, 2024 Basilea Pharmaceutica Ltd (SIX: BSLN), Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced that continued strong sales performance in Asia Pacific and China for its licensing partner Pfizer's antifungal drug Cresemba® (isavuconazole) has exceeded sales thresholds, resulting in a milestone payment of $1.25 million. “Achieving our third milestone payment threshold in Asia Pacific and China this year underscores the strong sales performance and growth of Cresemba in the region,” said David Veitch, CEO of Basilea. “We are pleased that Cresemba continues to meet…

Basilea Pharmaceutica AG, AllschwilAllschwil, Switzerland, August 21, 2024Basilea Pharmaceutica Ltd (SIX: BSLN), Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced that continued strong sales performance in Asia Pacific and China for its licensing partner Pfizer's antifungal drug Cresemba® (isavuconazole) has exceeded sales thresholds, resulting in a milestone payment of $1.25 million.”Achieving our third milestone payment threshold in Asia Pacific and China this year underscores the strong sales performance and growth of Cresemba in the region,” said David Veitch, CEO of Basilea. “We are pleased that Cresemba continues to…